References of "Beckers, Albert"
     in
Bookmark and Share    
Peer Reviewed
See detailLe traitement des prolactinomes par un nouvel agoniste dopaminergique (le CV 205-502) : résultats chez 48 patients.
Beckers, Albert ULg; Ghuysen, A. E.; Abs, R. et al

in Médecine et Hygiène (1992), 50

Detailed reference viewed: 20 (0 ULg)
Peer Reviewed
See detailLes adénomes hypophysaires à TSH.
Beckers, Albert ULg; Stevenaert, Achille ULg

in Revue Française d'Endocrinologie Clinique, Nutrition, et Métabolisme (La) (1992), 33(2), 151-156

Detailed reference viewed: 3 (0 ULg)
See detailEvaluatie van de nieuwe dopamine-agonist CV 205-502 in de behandeling van prolactinomen
Verhelst, J.; Abs, R.; Beckers, Albert ULg et al

in Acta Antwerpiensia (1992), 9

Detailed reference viewed: 13 (0 ULg)
Peer Reviewed
See detailTreatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
Beckers, Albert ULg; Petrossians, Patrick ULg; Abs, R. et al

in Journal of Clinical Endocrinology and Metabolism (1992), 75(1), 275-80

Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the long-acting and repeatable form of bromocriptine (Parlodel-LAR) in doses ranging from 50-150 mg. They ... [more ▼]

Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the long-acting and repeatable form of bromocriptine (Parlodel-LAR) in doses ranging from 50-150 mg. They were divided into two groups: group I consisted of 22 patients who received Parlodel LAR before transsphenoidal adenomectomy; group II was composed of 7 patients with earlier neurosurgery and of 2 patients from group I not cured by transsphenoidal adenomectomy. Duration of therapy varied from 1-12 months, and a total of 104 injections was given. At nadir day, serum PRL levels were situated between less than 1% and 43% of pretreatment values. At day 28 after the first injection, serum PRL levels varied between less than 1% to 139% of initial values. No difference could be detected between the two groups regarding the percent of PRL inhibition. Long-term treatment with Parlodel-LAR resulted in a sustained inhibition of PRL secretion, except for 1 case. Resumption of menstrual cycles occurred in 4 out of 15 women and correction of hypogonadism in 4 out of 14 men. Amelioration of disturbed visual fields was recorded in 3 out of 8 patients. Diminution of the adenoma volume was radiologically documented in 14 out of 22 cases. Only few and mild side effects were recorded. One patient with partial adrenal deficiency suffered from a syncope, but this was prevented by hydrocortisone supplementation during the subsequent Parlodel-LAR administration. In conclusion, Parlodel-LAR proved effective in the treatment of macroprolactinomas, achieving rapid inhibition of PRL secretion, and in some patients amelioration of hypopituitarism, reduction in tumor size, and improvement in visual fields, and caused no serious side effects. It is a valuable preparation to surgery and can also be used in long-term medical therapy. [less ▲]

Detailed reference viewed: 5 (0 ULg)
See detailClinical experience with CV 205-502 (Sandoz) in the treatment of prolactinomas
mahler, c; verhelst, j; abs, r et al

in ninth Internation Congress of Endocrinology-Abstract book (1992)

Detailed reference viewed: 3 (0 ULg)
See detailHyperfunctioning unilateral adrenal macro-nodule in two patients with cushing's disease : hormonal and imaging characteristics.
Abs, R.; Verhelst, J.; Nobels, F. et al

Conference (1992)

Detailed reference viewed: 4 (0 ULg)
See detailThyrotorpin-secreting pituitary adenomas - Report of 8 cases.
Stevenaert, Achille ULg; Abs, R.; Mahler, Ch. et al

Conference (1992)

Detailed reference viewed: 5 (0 ULg)
See detailThyrotropin-secreting pituitary adenomas. Report of 8 cases.
Beckers, Albert ULg; Abs, R.; Mahler, Ch. et al

Conference (1992)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailCorrespondence analysis for quantification in electron energy loss spectroscopy and imaging.
Gelsema, E. S.; Beckers, Albert ULg; Sorber, C. W. et al

in Methods of Information in Medicine (1992), 31(1), 29-35

Electron energy loss spectroscopy (EELS) is a technique to investigate the physical properties of material. Using this technique it is possible to detect the presence of a specific element in a specimen ... [more ▼]

Electron energy loss spectroscopy (EELS) is a technique to investigate the physical properties of material. Using this technique it is possible to detect the presence of a specific element in a specimen. When used in combination with an electron microscope, energy filtered images may be obtained, which in principle may be used to quantify the local element concentration. This involves a process of background correction, conventionally performed assuming a specific parametric behavior of the spectral intensity as a function of electron energy loss. In this article a parameter-free method is described for background correction based on the formalism of correspondence analysis. Such a method may be used in parts of the spectrum where the functional dependence of the spectral intensity is unknown. Use of this method for element detection has been suggested before. This article reports simulation experiments suggesting its suitability for quantitative determination of element distributions and element concentrations. [less ▲]

Detailed reference viewed: 12 (0 ULg)
See detailCauses and Incidence of growth hormone deficiency in the adults
Beckers, Albert ULg

Scientific conference (1991, November 19)

Detailed reference viewed: 2 (0 ULg)
See detailPresurgical Octreotide Treatment in Acromegaly
Beckers, Albert ULg

Scientific conference (1991, October)

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailEffect of treatment with octreotide on the morphology of growth hormone secreting pituitary adenomas : study of 24 cases.
Beckers, Albert ULg; Kovacs, K.; Horvwarth, E. et al

in Endocrine Pathology (1991), 2(3), 123-131

Twenty-four acromegalic patients were treated with octreotide subcutaneously for periods of 3 to 6 weeks (group I, 12 cases) or 6 months (group II, 12 cases) before transsphenoidal surgery. Radiological ... [more ▼]

Twenty-four acromegalic patients were treated with octreotide subcutaneously for periods of 3 to 6 weeks (group I, 12 cases) or 6 months (group II, 12 cases) before transsphenoidal surgery. Radiological studies performed in 19 patients before and at the end of this treatment period revealed no changes in 8 cases. In 8 other cases, a slight reduction in tumorsize was observed, and in 3 cases an important shrinkage was documented. At surgery, the adenomatous tissue appeared softer than in nonpretreated patients, facilitating the operation. Pathological examination revealed widening of perivascular spaces with accumulation of fibrous tissue and more crinophagy than in nonpretreated patients but failed to reveal morphologically pronounced cell involution as observed in prolactin-producing adenomas treated with dopamine agonists. No significant difference in frequency or extent of cellular changes was noted between the two groups. These morphological findings seem to be more consistent with a functional inhibition of growth hormone release than with cellular alterations induced by octreotide. [less ▲]

Detailed reference viewed: 5 (0 ULg)